Trial reportAllergy2022
Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy.
Trial report in Allergy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Immunological Mechanisms and Outcomes of T-cell-Targeted Immunotherapy in Food Allergy: A Systematic Review.Clinical reviews in allergy & immunology · 2025Pooled it
- Systematic Review and Meta-Analysis of Oral Immunotherapy Effect on Food Allergy-Related Quality of Life.Allergy · 2025Pooled it
- Re-evaluating treatment success in trials of peanut oral-immunotherapy: impact of different definitions on efficacy outcomes.Current opinion in allergy and clinical immunology · 2025Pooled it
- Quality Appraisal of Quality of Life Research in Children and Adolescents with Food Allergy: A Systematic Review.International archives of allergy and immunology · 2024Pooled it
- Dosing Reactions and Missed Doses Affect Peanut Oral Immunotherapy Outcomes.The journal of allergy and clinical immunology. In practice · 2026Trial
- Sex assigned at birth may modify health-related quality of life in children treated with peanut oral immunotherapy.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2025Trial
- Trial
- Safety and efficiency of peanut oral immunotherapy in preschool children with slow up-dosing and low maintenance dosing: a randomised controlled trial.The Lancet regional health. Europe · 2026Article
- Article
- Real-life safety of peanut oral immunotherapy: Results from a French multicenter observational study.The journal of allergy and clinical immunology. Global · 2026Article
- Advances in Shellfish Allergy Therapy: From Current Approaches to Future Strategies.Clinical reviews in allergy & immunology · 2025Review
- Observational
- ADP101 multifood oral immunotherapy for food-allergic patients: Harmony phase 1/2 randomized clinical trial.The journal of allergy and clinical immunology. Global · 2025Article
- Shrimp oral immunotherapy outcomes in the phase 2 clinical trial: MOTIF.Frontiers in allergy · 2025Article
- Recent advances in food allergen immunotherapy.Clinical and experimental pediatrics · 2024Article
- Identifying thresholds of reaction for different foods.Journal of food allergy · 2024Article
- Evaluation and Modification of a Shared Decision-Making Tool for Peanut Allergy Management.Current allergy and asthma reports · 2024Review
- Food Allergen Immunotherapy in the Treatment of Patients with IgE-Mediated Food Allergy.Medicina (Kaunas, Lithuania) · 2024Review
- Ethical Implications of Continuing Oral Immunotherapy After the Development of Eosinophilic Esophagitis.The journal of allergy and clinical immunology. In practice · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe benefit of daily administration of Peanut (Arachis hypogaea) Allergen Powder-dnfp (PTAH)-formerly AR101-has been established in clinical trials, but limited data past the first year of treatment are available. This longitudinal analysis aimed to explore the impact of continued PTAH therapeutic maintenance dosing (300 mg/day) on efficacy, safety/tolerability, and food allergy-related quality of life.
methodsWe present a subset analysis of PALISADE-ARC004 participants (aged 4-17 years) who received 300 mg PTAH daily for a total of ~1.5 (Group A, n = 110) or ~2 years (Group B, n = 32). Safety assessments included monitoring the incidence of adverse events (AEs), accidental exposures to food allergens, and adrenaline use. Efficacy was assessed by double-blind, placebo-controlled food challenge (DBPCFC); skin prick testing; peanut-specific antibody assays; and Food Allergy Quality of Life Questionnaire (FAQLQ) and Food Allergy Independent Measure (FAIM) scores.
resultsContinued maintenance with PTAH increased participants' ability to tolerate peanut protein: 48.1% of completers in Group A (n = 50/104) and 80.8% in Group B (n = 21/26) tolerated 2000 mg peanut protein at exit DBPCFC without dose-limiting symptoms. Immune biomarkers showed a pattern consistent with treatment-induced desensitization. Among PTAH-continuing participants, the overall and treatment-related exposure-adjusted AE rate decreased throughout the intervention period in both groups. Clinically meaningful improvements in FAQLQ and FAIM scores over time suggest a potential link between increased desensitization as determined by the DBPCFC and improved quality of life.
conclusionsThese results demonstrate that daily PTAH treatment for peanut allergy beyond 1 year leads to an improved safety/tolerability profile and continued clinical and immunological response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.